Cargando…
A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome
BACKGROUND: About 80% of patients with GIST would experience tumor recurrence or metastasis after radical resection. The most common site of the metastasis is the liver. Imatinib mesylate has been proved effective for advanced GIST. The present study was designed to further observe the effectiveness...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876083/ https://www.ncbi.nlm.nih.gov/pubmed/20465813 http://dx.doi.org/10.1186/1471-2407-10-199 |
_version_ | 1782181658787577856 |
---|---|
author | Zhu, Jiang Yang, Yu Zhou, Lin Jiang, Ming Hou, Mei |
author_facet | Zhu, Jiang Yang, Yu Zhou, Lin Jiang, Ming Hou, Mei |
author_sort | Zhu, Jiang |
collection | PubMed |
description | BACKGROUND: About 80% of patients with GIST would experience tumor recurrence or metastasis after radical resection. The most common site of the metastasis is the liver. Imatinib mesylate has been proved effective for advanced GIST. The present study was designed to further observe the effectiveness of the imatinib mesylate treatment on the recurrent GIST and the correlation between the liver metastasis and the outcome. METHODS: Forty-two patients who had recurrent GIST after the first radical resection were enrolled. According to the recurrent sites, the patients were divided into 3 groups: group LG (recurrent liver GISTs), group AG (recurrent abdominal GISTs) and group ALG (recurrent abdominal and liver GISTs). All the patients were given imatinib mesylate at an initial dose of 400 mg per day. Their clinical data was prospectively collected. A follow-up over 3 years was conducted. Tumor response, time to progression and survival were evaluated. RESULTS: The long-term Imatinib mesylate treatment was safe and well tolerated. At a median follow-up time for 39.5 months, the 3-year survival rate was 66.7%. Median TTP and OS were 37 months (95% CI: 28.2~45.8 months) and 48 months (95% CI: 37.0~58.9 months), respectively. There was no statistical difference in tumor response among the 3 groups. The similar TTP (P = 0.291) and OS (P = 0.160) were observed in the 3 groups. CONCLUSIONS: The imatinib mesylate treatment could prolong the survival of the patients who have recurrent GIST after the radical surgery in spite of an existence of the liver metastasis. Survival was not significantly affected by liver metastasis when imatinib mesylate was warranted. |
format | Text |
id | pubmed-2876083 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28760832010-05-26 A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome Zhu, Jiang Yang, Yu Zhou, Lin Jiang, Ming Hou, Mei BMC Cancer Research Article BACKGROUND: About 80% of patients with GIST would experience tumor recurrence or metastasis after radical resection. The most common site of the metastasis is the liver. Imatinib mesylate has been proved effective for advanced GIST. The present study was designed to further observe the effectiveness of the imatinib mesylate treatment on the recurrent GIST and the correlation between the liver metastasis and the outcome. METHODS: Forty-two patients who had recurrent GIST after the first radical resection were enrolled. According to the recurrent sites, the patients were divided into 3 groups: group LG (recurrent liver GISTs), group AG (recurrent abdominal GISTs) and group ALG (recurrent abdominal and liver GISTs). All the patients were given imatinib mesylate at an initial dose of 400 mg per day. Their clinical data was prospectively collected. A follow-up over 3 years was conducted. Tumor response, time to progression and survival were evaluated. RESULTS: The long-term Imatinib mesylate treatment was safe and well tolerated. At a median follow-up time for 39.5 months, the 3-year survival rate was 66.7%. Median TTP and OS were 37 months (95% CI: 28.2~45.8 months) and 48 months (95% CI: 37.0~58.9 months), respectively. There was no statistical difference in tumor response among the 3 groups. The similar TTP (P = 0.291) and OS (P = 0.160) were observed in the 3 groups. CONCLUSIONS: The imatinib mesylate treatment could prolong the survival of the patients who have recurrent GIST after the radical surgery in spite of an existence of the liver metastasis. Survival was not significantly affected by liver metastasis when imatinib mesylate was warranted. BioMed Central 2010-05-13 /pmc/articles/PMC2876083/ /pubmed/20465813 http://dx.doi.org/10.1186/1471-2407-10-199 Text en Copyright ©2010 Zhu et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Zhu, Jiang Yang, Yu Zhou, Lin Jiang, Ming Hou, Mei A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome |
title | A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome |
title_full | A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome |
title_fullStr | A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome |
title_full_unstemmed | A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome |
title_short | A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome |
title_sort | long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (gist): the liver metastasis and the outcome |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876083/ https://www.ncbi.nlm.nih.gov/pubmed/20465813 http://dx.doi.org/10.1186/1471-2407-10-199 |
work_keys_str_mv | AT zhujiang alongtermfollowupoftheimatinibmesylatetreatmentforthepatientswithrecurrentgastrointestinalstromaltumorgistthelivermetastasisandtheoutcome AT yangyu alongtermfollowupoftheimatinibmesylatetreatmentforthepatientswithrecurrentgastrointestinalstromaltumorgistthelivermetastasisandtheoutcome AT zhoulin alongtermfollowupoftheimatinibmesylatetreatmentforthepatientswithrecurrentgastrointestinalstromaltumorgistthelivermetastasisandtheoutcome AT jiangming alongtermfollowupoftheimatinibmesylatetreatmentforthepatientswithrecurrentgastrointestinalstromaltumorgistthelivermetastasisandtheoutcome AT houmei alongtermfollowupoftheimatinibmesylatetreatmentforthepatientswithrecurrentgastrointestinalstromaltumorgistthelivermetastasisandtheoutcome AT zhujiang longtermfollowupoftheimatinibmesylatetreatmentforthepatientswithrecurrentgastrointestinalstromaltumorgistthelivermetastasisandtheoutcome AT yangyu longtermfollowupoftheimatinibmesylatetreatmentforthepatientswithrecurrentgastrointestinalstromaltumorgistthelivermetastasisandtheoutcome AT zhoulin longtermfollowupoftheimatinibmesylatetreatmentforthepatientswithrecurrentgastrointestinalstromaltumorgistthelivermetastasisandtheoutcome AT jiangming longtermfollowupoftheimatinibmesylatetreatmentforthepatientswithrecurrentgastrointestinalstromaltumorgistthelivermetastasisandtheoutcome AT houmei longtermfollowupoftheimatinibmesylatetreatmentforthepatientswithrecurrentgastrointestinalstromaltumorgistthelivermetastasisandtheoutcome |